Kintor has started Phase 3 trial in China for Pyrilutamide

[HansMetjen]

A phase 3 in US for Pyri next year and phase 2 trials both China and US for the AR degrader, cmon Kintor you can make it happen.

Those Chinks working at Kintor deserve us bowing down to them. Great work, my yellow friends! You are our best hope against the slaphead curse. Kudos!

 

[HansMetjen]

You germans are fucked for sure but still not as bad as in Sweden.

True, but our leftist Politicians are soooooo dumb by wanting to catch up with Sweden when it comes to "enrichment numbers". German politicians still want to take in more of those primitive thirdworlders. It's mindboggling.

Germany still Europe's top spot for asylum-seekers – DW – 10/17/2021

The number of asylum applications in Germany has risen again this year. Along with traditional routes through Greece, Italy and Spain, Belarus has become a major migration route in the last few months.

www.dw.com

I am not sure how this madness is going to end, but it won't be pleasant.

 

[HansMetjen]

When can we expect to get this commercially? I understand that phase 3 needs to be completed before that but what could be the best case scenario for product release?

2024 in China and 2025 in USA.

 

[TheBlackSuit]

I can't believe it. Actual good news.

Wasn't there a group buy for this stuff that didn't get good results? Does that suggest that they weren't sold the real deal?

 

[bigentries]

Do you think the group buy is a scam?

I don’t know what happen but CB0301 is similar to pirylutamida. It works perfect at 7,5% (at least the first year. We don’t know why but CB loss efficacy after 1 year). BUT I don’t know a single guy that have recovered hair like finasteride using only CB.

Any reasonable explanation for the non-working pirylutamide group buy?

I’ve seen pics from the group buy, none has a serious degree of baldness to make a difference, there’s even one guy with an NW0 and ridiculous density trying it

 

[Dat5Years]

Does this always have to f*****g devolve. Some rightoid weirdo calling people “chinks”, and arguing over group buys. Talk about the f*****g product, can we get it now and how good it is. f*** me this forum is a mess

 

[HansMetjen]

Some rightoid weirdo calling people “chinks”, and arguing over group buys.

This was meant in a lovely manner

I love my yellow chinks developing into a master race

Calm down, my woke friend.

 

[Min0]

This was meant in a lovely manner

I love my yellow chinks developing into a master race

Calm down, my yellow friend.

obviously the master race is the race that doesn't go bald. hitler got it all wrong.

 

[Dat5Years]

This was meant in a lovely manner

I love my yellow chinks developing into a master race

Calm down, my yellow friend.

Edgy lol. I’m not Asian but you’re problems are deeper than hair. NW0 ain’t gonna save a little spastic like you im afraid lel.

 

[Dat5Years]

Bro its not devolving im just shitting on roey as my long tradition lmao, there is nothing we can do but wait now for release of final/official product as group buys have shown they are incompetent.

Conclusion is that it works its just waiting game from now on.
Or ofcourse you can join their 100% pure group buy and say it doesnt work 2 months later.

I’m not arsed about the group buy, it’s not a scam tho. Either way we get legit good results and the discussion is absolutely cheeks

 

[Cardinal~]

KX-826 Phase 2 Results​

Purpose

The purpose of this study is to evaluate the safety, exposure, and efficacy of flecainide (KX-826) in the treatment of adult men with androgenetic alopecia (Androgenetic Alopecia) in China.
The objective of this study is to evaluate the safety, population exposure and efficacy of forretinoin (KX-826) in the treatment of adult male patients with Androgenetic Alopecia in China and to determine the recommended dose for a phase II trial.

Methods

This is a multicenter, randomized, two-word, placebo-controlled phase I clinical trial (KX-826-CN-1002).

The study is a phase I clinical trial (KX-826-CN-1002). Chinese adult men with Androgenetic Alopecia who met the Hamilton-Norwood classification (Class IIV, IV, YV) were randomized in a 1:1:1:1 ratio to the KX-826-CN-1002.
The patients were randomly assigned to the KX-826 2.5 mg (0.25% concentration) BID group, the 5 mg (0.5% concentration) QD group, the 5 mg (0.5% concentration)
BID group and the anandamide group (QD and BID groups).

The study design and efficacy endpoints are shown in Figure 1.

Figure 1 Study design and efficacy endpoints

Male, >18 years of age, in good general health
Clinical diagnosis of androgenic baldness; severity of baldness according to Hamilton-Norwood grading IIv, IV, YV
"Willingness to use the same shampoo and maintain the same hair shape, color, and length throughout the trial
"No parenting plan during the study period and within 3 months of the last dose and able to use effective contraception


Efficacy Endpoints:

* Primary endpoint; mean change from baseline in the target area of non-compulsory hair count (TAHC) after 24 weeks of treatment
* Secondary endpoints: change from baseline in TAHC after 6, 12, and 18 weeks of treatment; change from baseline in non-compassionate hair diameter (TAHW) in target area after 6, 12, 18, and 24 weeks of treatment
Change from baseline in TAHW; Hair growth assessment (HGA), including subject self-assessment, investigator assessment, and
Third-party physician assessment

Baseline patient characteristics

120 Chinese adult male Androgenetic Alopecia patients (mean height: 172.95 cm; mean weight: 75.05 kg), randomly assigned to
KX-826 2.5 mg (0.25% concentration) BID group (n=30), 5 mg (0.5% concentration) QD group (n=30), 5 mg (0.5% concentration)
(0.5% concentration) BID" (n=30) group, placebo QD group (n=10) and placebo BID group (n=20), with details of the patients
The baseline characteristics are shown in Table 1.


Security Analysis

*. Systemic exposure to KX-826 and its metabolite KX-982 reached steady-state after 14 days of topical application; transdermal blood concentrations were low in all dose groups.

The drug concentrations were low, with detectable KX-826 blood levels ranging from 0.3-4.1 ng/mL and KX-982 blood levels ranging from 0.4-10.4 ng/mL.

The blood levels of KX-982 were 0.4-10.4 ng/mL. The three dose reductions due to adverse events (AEs) were classified as Grade 1 contact dermatitis, Grade 2 rash, and Grade 1 smoldering rash according to the Common Adverse Event Evaluation Criteria 5.0.
Grade 1 rash and Grade 1 itch.

The incidence of adverse drug reactions (ADRs) was 16.1%, with the most common ADR being pruritus/itchy skin (5.9%), followed by contact dermatitis (2.5%); and 1 ADR (2.5%).
The most common ADR was carcinoma itch (5.9%), followed by contact dermatitis (2.5%); one case had grade 3 hypertriglyceridemia and one case had grade 4 hypertriglyceridemia, but the baseline triglyceride value was high (6.99 mmolL).
(6.99 mmolL).
No serious adverse events, no serious ADRs and no deaths.


Conclusion

* Chinese adult male Androgenetic Alopecia patients (Hamilton-Norwood classification IIv, IV, YV) treated with topical KX-826 5 mg BID
After 24 weeks of treatment, there was a significant increase in TAHC in the target area compared to placebo, and the overall safety of the KX-826 dose groups was good.
No new safety events were observed outside of the expected period. In the 5 mg (0.5% concentration) BID group, TAHC increased by 15.34 roots/cm?at week 24 compared to the placebo group.
There was a statistically significant difference (p = 0.024).

The difference was statistically significant (p = 0.024). KX-826 5 mg BID is recommended as the dose for confirmatory clinical trials.

Werent those results supposed to come out on spetember 2nd?

 

[HansMetjen]

Edgy lol. I’m not Asian but you’re problems are deeper than hair. NW0 ain’t gonna save a little spastic like you im afraid lel.

Sure thing, bro

\o

 

[HansMetjen]

 

[hairlossisevil]

Not sure why I thought this was a once a day thing. Aplying this twice per day is going to be a major PITA. Not to mention ridiculously expensive compared to finasteride.

 

[5minutesbeforemiracle]

Not sure why I thought this was a once a day thing. Aplying this twice per day is going to be a major PITA. Not to mention ridiculously expensive compared to finasteride.

You can still apply it once a day, just like some people apply minoxidil once a day. It works but just less effective. Taking other treatments at the same time will reduce the need to apply it once a day I guess.

 

[hairlossisevil]

You can still apply it once a day, just like some people apply minoxidil once a day. It works but just less effective. Taking other treatments at the same time will reduce the need to apply it once a day I guess.

I mean QD (once per day) is still pretty damn effective. Bought some powder from Anagen and been using it 4 days now. 0.5ml on my hairline and 0.5ml on my crown (0.5%). I'll see if I can notice any difference in shedding and/or overall thickness. This is the only change in my regimen so if something good happens it's definitely KX-826.

 

[Ralph Wiggum]

When do we expect the phase 3 results?

 

[HansMetjen]

Not sure why I thought this was a once a day thing. Aplying this twice per day is going to be a major PITA. Not to mention ridiculously expensive compared to finasteride.

You can apply it once a day at a higher dosage.

 

[HansMetjen]

When do we expect the phase 3 results?

At the end of 2023.

 

[Trichosan]

Then wait for FDA clearance 2033.